Why are mid-sized pharmaceutical companies hesitant to join the Trump administration's Medicaid drug pricing pilot program?

Mid-sized companies like Ionis Pharmaceuticals cite their limited drug portfolios and different business models—relying heavily on licensing deals with overseas partners—as reasons they see 'no real upside' in participating, since the program restricts pricing autonomy without offering commensurate benefits.

What is the scope and timeline of the Medicaid drug pricing pilot program, and how much savings does the White House project?

The CMS Medicaid pilot is a 5-year program requiring participating manufacturers to offer drug prices based on what other countries pay; though the White House claims the already-signed most-favored-nation agreements cover 86% of the U.S. branded drug market by sales and project $64.3 billion in federal and state savings over 10 years, that figure is speculative, with about half the savings dependent on state participation decisions due by September, and the pilot itself lasting only five years.

Trump's Push for Lowest Drug Prices Hits Snag with Mid-Sized Companies

Jun 30, 2026

President Trump's drug pricing initiative faces resistance from mid-sized pharmaceutical firms during a Medicaid pilot, despite major players signing deals covering 86% of the market. Smaller innovators cite limited upside as potential mandatory Medicare pricing mandates loom.

reuters

2026-05-18

Trump's Psychedelic Drug Order Boosts Investor Interest with Promise of Faster Reviews

2026-06-30

Trump's Push for Lowest Drug Prices Hits Snag with Mid-Sized Companies

2026-09-19

Trump Announces All 50 States Joining Medicaid Drug Pricing Model

Trump's Push for Lowest Drug Prices Hits Snag with Mid-Sized Companies

FAQ